잠시만 기다려 주세요. 로딩중입니다.

Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease

Clinical and Molecular Hepatology 2020년 26권 4호 p.430 ~ 443
김경수, 이병완,
소속 상세정보
김경수 ( Kim Kyung-Soo ) - CHA University School of Medicine CHA Bundang Medical Center Department of Internal Medicine
이병완 ( Lee Byung-Wan ) - Yonsei University College of Medicine Department of Internal Medicine

Abstract


Nonalcoholic fatty liver disease (NAFLD) is the most common liver disorder and is associated with various metabolic diseases, including type 2 diabetes mellitus. There are no approved drugs for NAFLD, and the only approved treatment option is weight reduction. As insulin resistance plays an important role in the development of NAFLD, many anti-diabetic drugs have been evaluated for the treatment of NAFLD. Improvement of liver enzymes has been demonstrated by many anti-diabetic drugs, but histological assessment still remains insufficient. Pioglitazone could become the first-line therapy for T2DM patients with NAFLD, based on evidence of histological improvement in patients with biopsy-proven nonalcoholic steatohepatitis (NASH). Liraglutide, another promising alternative, is not yet recommended in patients with NAFLD/NASH due to limited evidence. Therefore, well-designed randomized controlled trials should be performed in the near future to demonstrate if and how anti-diabetic drugs can play a role in the treatment of NAFLD.

키워드

Anti-diabetic drug; Diabetes mellitus; Metabolic diseases; Non-alcoholic fatty liver disease; Treatment

원문 및 링크아웃 정보

등재저널 정보